ArticleWorld journal of clinical cases2022
Effect of celecoxib on improving depression: A systematic review and meta-analysis.
Article in World journal of clinical cases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Celecoxib adjunct to antidepressants for major depressive disorder: Systematic review and meta-analysis.Brain, behavior, & immunity - health · 2026Article
- Pharmacotherapeutic Management of Depression in Patients With Cancer: A Review of Mechanistic and Clinical Evidence.Cancer reports (Hoboken, N.J.) · 2026Review
- The synaptic triad in depression: how stress-related pathways converge on BDNF, NMDA receptor, and MMP-9.Pharmacological reports : PR · 2026Review
- Esflurbiprofen exerts a fast-onset antidepressant effect by blocking SERT-nNOS interaction.Acta pharmacologica Sinica · 2026Article
- Response to immune-based augmentation treatment for depression: a potential role of immunosenescence.Neuroscience applied · 2026Article
- Celecoxib Ameliorates Chronic Restraint Stress-Induced Depression-Like Behavior in Sprague-Dawley Rats.Neuropsychiatric disease and treatment · 2026Article
- Do immune system and microbiome-gut-brain axis interactions associate with major depressive disorder?Journal of translational medicine · 2025Review
- Inflammatory and Immune Biomarkers in Mood Disorders: From Mechanistic Pathways to Clinical Translation.Cells · 2025Review
- Central-peripheral neuroimmune dynamics in psychological stress and depression: insights from current research.Molecular psychiatry · 2025Review
- Innovative approaches in the treatment-resistant depression: exploring different therapeutic pathways.GeroScience · 2025Review
- Childhood insulin resistance and neural stem cell dysfunction in psychiatric disorders: Role ofWorld journal of stem cells · 2025Review
- Interconnections of screen time with neuroinflammation.Molecular and cellular biochemistry · 2025Review
- Xiangshao Granules Ameliorate Post-stroke Depression by Inhibiting Activation of Microglia and IDO1 Expression in Hippocampus and Prefrontal Cortex.Chinese journal of integrative medicine · 2025Article
- Mushrooms, Microdosing, and Mental Illness: The Effect of Psilocybin on Neurotransmitters, Neuroinflammation, and Neuroplasticity.Neuropsychiatric disease and treatment · 2025Review
- Metabolic complications of psychotropic medications in psychiatric disorders: Emerging role ofWorld journal of psychiatry · 2024Review
- Review
- Neurodevelopmental and Neuropsychiatric Disorders.Advances in neurobiology · 2024Review
- Challenges and Opportunities for Celecoxib Repurposing.Pharmaceutical research · 2023Review
- Fight the Fire: Association of Cytokine Genomic Markers and Suicidal Behavior May Pave the Way for Future Therapies.Journal of personalized medicine · 2023Review
- Celecoxib for Mood Disorders: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Journal of clinical medicine · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAnti-inflammation drugs were uncovered to be a potential therapy for depression. Celecoxib as a selective COX2 inhibitor is also one anti-inflammation drugs. Celecoxib is widely used in the clinic, which is well known by medical workers. It is uncertain whether celecoxib has efficacy in improving depression.
aimTo estimate the effect of celecoxib on improving depression.
methodsAll literature was searched until 2022. The databases included PubMed, OVID database, Cochrane library, Web of Science, CNKI, Clinicaltrials.gov database and Wanfang database. The random effects model was used to estimate the standardized mean differences with 95%CIs. With determined diagnostic criteria, studies containing patients with depression in the celecoxib group and the control group were included in the meta-analysis. The primary outcome measures were set for depression scale scores.
resultsTwenty-nine randomized controlled studies were included in the meta-analysis (including 847 subjects with depression and 810 control subjects). The meta-analysis showed that celecoxib had an effect of anti-depression. At the same time, heterogeneity was observed (
conclusionCelecoxib could be effective for improving depression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.